ArticleFood & nutrition research2025
Article in Food & nutrition research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cisplatin is widely utilized in the treatment of solid malignant tumors due to its potent anticancer effects through the inhibition of cell division. However, its clinical use is often limited by significant adverse effects, particularly nephrotoxicity. Recent research has focused on natural products as potential mitigators of cisplatin-induced kidney toxicity. Objective: This study aimed to investigate the protective effects of Methods: HEK-293 cells were treated with cisplatin (50 μM) with or without Results: Cisplatin treatment (50 μM) significantly increased ROS production compared to untreated cells within 24 h. Both AHWE and AHEE treatments markedly attenuated ROS generation. Additionally, AHWE and AHEE significantly inhibited NO production and downregulated the expression of inflammation-related genes. The treatments also suppressed mitogen-activated protein kinase (MAPK) protein expression. Pretreatment with AHWE and AHEE decreased the Bax/Bcl-2 expression ratio, demonstrating a dose-dependent inhibition of apoptotic features. Conclusion: The findings suggest that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.